FeyeCon's joint venture Echo Pharmaceuticals BV announces that initial clinical trials have proven the efficiency of its patented Alitra™ technology to enhance bioavailability. Results show that the bioavailability of CDB product, Arvisol® is increased by 30%. This is of massive importance because it reduces the costs of the medication and increases the convenience for patients.

Weesp, The Netherlands – July 2015 – In the last years, the interest grew in the therapeutic benefits of cannabinoids and especially in the medical properties for different therapeutic indications of CBD. CBD has been shown to provide anti-convulsing, anti-arthritic and neuroprotective properties while not inducing any psychoactivity effect.  

Current medications using CBD request high CBD doses per patient. Echo Pharmaceuticals has patented a drug delivery technology Alitra™, to incorporate lipophilic compounds into an effective pharmaceutical dosage form. Alitra™ significantly improves absorption and distribution of compounds with low water solubility. The efficacy of Alitra™ technology to enhance bioavailability, of different lipophilic compounds, has been clinically demonstrated and implemented in Echo’s leading products Namisol® (oral tablet containing pure THC) and Arvisol® (oral tablet containing pure CBD).

The improvement of the CBD bioavailability by 30% in Echo’s Arvisol® oral tablet is of high importance because it reduces significantly the therapeutic dose of CBD. It also has a positive impact in dropping the medication cost which will directly benefit the patients.

More information about Echo Pharmaceuticals and its products.

		stdClass Object
(
    [vid] => 92
    [uid] => 1
    [title] => Echo Pharmaceuticals 
    [log] => 
    [status] => 1
    [comment] => 1
    [promote] => 1
    [sticky] => 0
    [nid] => 92
    [type] => nieuws
    [language] => nl
    [created] => 1438607126
    [changed] => 1438607279
    [tnid] => 0
    [translate] => 0
    [revision_timestamp] => 1438607279
    [revision_uid] => 1
    [body] => Array
        (
            [nl] => Array
                (
                    [0] => Array
                        (
                            [value] => 

FeyeCon's joint venture Echo Pharmaceuticals BV announces that initial clinical trials have proven the efficiency of its patented Alitra™ technology to enhance bioavailability. Results show that the bioavailability of CDB product, Arvisol® is increased by 30%. This is of massive importance because it reduces the costs of the medication and increases the convenience for patients.

Weesp, The Netherlands – July 2015 – In the last years, the interest grew in the therapeutic benefits of cannabinoids and especially in the medical properties for different therapeutic indications of CBD. CBD has been shown to provide anti-convulsing, anti-arthritic and neuroprotective properties while not inducing any psychoactivity effect.  

Current medications using CBD request high CBD doses per patient. Echo Pharmaceuticals has patented a drug delivery technology Alitra™, to incorporate lipophilic compounds into an effective pharmaceutical dosage form. Alitra™ significantly improves absorption and distribution of compounds with low water solubility. The efficacy of Alitra™ technology to enhance bioavailability, of different lipophilic compounds, has been clinically demonstrated and implemented in Echo’s leading products Namisol® (oral tablet containing pure THC) and Arvisol® (oral tablet containing pure CBD).

The improvement of the CBD bioavailability by 30% in Echo’s Arvisol® oral tablet is of high importance because it reduces significantly the therapeutic dose of CBD. It also has a positive impact in dropping the medication cost which will directly benefit the patients.

More information about Echo Pharmaceuticals and its products.

[summary] => [format] => full_html [safe_value] =>

FeyeCon's joint venture Echo Pharmaceuticals BV announces that initial clinical trials have proven the efficiency of its patented Alitra™ technology to enhance bioavailability. Results show that the bioavailability of CDB product, Arvisol® is increased by 30%. This is of massive importance because it reduces the costs of the medication and increases the convenience for patients.

Weesp, The Netherlands – July 2015 – In the last years, the interest grew in the therapeutic benefits of cannabinoids and especially in the medical properties for different therapeutic indications of CBD. CBD has been shown to provide anti-convulsing, anti-arthritic and neuroprotective properties while not inducing any psychoactivity effect.  

Current medications using CBD request high CBD doses per patient. Echo Pharmaceuticals has patented a drug delivery technology Alitra™, to incorporate lipophilic compounds into an effective pharmaceutical dosage form. Alitra™ significantly improves absorption and distribution of compounds with low water solubility. The efficacy of Alitra™ technology to enhance bioavailability, of different lipophilic compounds, has been clinically demonstrated and implemented in Echo’s leading products Namisol® (oral tablet containing pure THC) and Arvisol® (oral tablet containing pure CBD).

The improvement of the CBD bioavailability by 30% in Echo’s Arvisol® oral tablet is of high importance because it reduces significantly the therapeutic dose of CBD. It also has a positive impact in dropping the medication cost which will directly benefit the patients.

More information about Echo Pharmaceuticals and its products.

[safe_summary] => ) ) ) [field_banner] => Array ( [und] => Array ( [0] => Array ( [fid] => 11 [uid] => 1 [filename] => recycling_waste.jpg [uri] => public://default_images/recycling_waste.jpg [filemime] => image/jpeg [filesize] => 342626 [status] => 1 [timestamp] => 1375988880 [rdf_mapping] => Array ( ) [is_default] => 1 [alt] => [title] => ) ) ) [field_liggende_image] => Array ( ) [field_staande_image] => Array ( ) [field_datum] => Array ( [und] => Array ( [0] => Array ( [value] => 2015-08-03T00:00:00 [timezone] => Europe/Amsterdam [timezone_db] => Europe/Amsterdam [date_type] => date ) ) ) [field_blok_grootte] => Array ( [und] => Array ( [0] => Array ( [value] => big ) ) ) [field_blok_achtergrond] => Array ( [und] => Array ( [0] => Array ( [value] => bg_red ) ) ) [field_blok_tekstkleur] => Array ( [und] => Array ( [0] => Array ( [value] => white ) ) ) [field_video] => Array ( ) [field_subtitel] => Array ( [und] => Array ( [0] => Array ( [value] => Improved uptake of cannabinoid based medicine [format] => [safe_value] => Improved uptake of cannabinoid based medicine ) ) ) [field_gerelateerde_industrie_n] => Array ( [und] => Array ( [0] => Array ( [target_id] => 20 [entity] => stdClass Object ( [vid] => 20 [uid] => 1 [title] => Pharmaceutical and Biomedical [log] => [status] => 1 [comment] => 1 [promote] => 1 [sticky] => 0 [nid] => 20 [type] => industries [language] => nl [created] => 1376039461 [changed] => 1492505610 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1492505610 [revision_uid] => 1 [body] => Array ( [nl] => Array ( [0] => Array ( [value] =>

Healthy people and a Healthy planet

That is what FeyeCon aims for. Using CO₂ based processes for drug isolation, purification and formulation we create completely new and improved pharmaceutical and biomedical products. Our CO₂ technology is mild and leaves no residual solvents. It offers a very versatile and tunable process.  

Our mild and versatile CO₂ technology achieves:

  • High drug bioavailability
  • Increased product shelf-life
  • Improved patient wellbeing
  • Straightforward GMP upscaling

Our particles are characterized by:

  • High bioavailability
  • Tunable particle properties: size, morphology, density, crystal structures, polymorphisms
  • Tunable drug release properties
  • Full structural preservation of sensitive drugs
  • Different routes of administration

GMP Clean Room Facility 

At our laboratory in Weesp, The Netherlands, we have cGMP facilities that operate supercritical CO₂ equipment available to external parties. Our facilities - including a certified class D cleanroom - allow for the cGMP production of clinical batches and contract manufacturing.

Read more about our Pharmaceutical and Biomedical Technology

[summary] => [format] => full_html [safe_value] =>

Healthy people and a Healthy planet

That is what FeyeCon aims for. Using CO₂ based processes for drug isolation, purification and formulation we create completely new and improved pharmaceutical and biomedical products. Our CO₂ technology is mild and leaves no residual solvents. It offers a very versatile and tunable process.  

Our mild and versatile CO₂ technology achieves:

  • High drug bioavailability
  • Increased product shelf-life
  • Improved patient wellbeing
  • Straightforward GMP upscaling

Our particles are characterized by:

  • High bioavailability
  • Tunable particle properties: size, morphology, density, crystal structures, polymorphisms
  • Tunable drug release properties
  • Full structural preservation of sensitive drugs
  • Different routes of administration

GMP Clean Room Facility 

At our laboratory in Weesp, The Netherlands, we have cGMP facilities that operate supercritical CO₂ equipment available to external parties. Our facilities - including a certified class D cleanroom - allow for the cGMP production of clinical batches and contract manufacturing.

Read more about our Pharmaceutical and Biomedical Technology

[safe_summary] => ) ) ) [field_banner] => Array ( [und] => Array ( [0] => Array ( [fid] => 369 [uid] => 1 [filename] => shutterstock_105030071.jpg [uri] => public://banner/shutterstock_105030071.jpg [filemime] => image/jpeg [filesize] => 6251924 [status] => 1 [timestamp] => 1489152377 [rdf_mapping] => Array ( ) [alt] => [title] => [width] => 4928 [height] => 3264 ) ) ) [field_blok_achtergrond] => Array ( [und] => Array ( [0] => Array ( [value] => bg_image ) ) ) [field_blok_grootte] => Array ( [und] => Array ( [0] => Array ( [value] => big ) ) ) [field_blok_tekstkleur] => Array ( [und] => Array ( [0] => Array ( [value] => black ) ) ) [field_liggende_image] => Array ( ) [field_staande_image] => Array ( [und] => Array ( [0] => Array ( [fid] => 370 [uid] => 1 [filename] => shutterstock_105030071.jpg [uri] => public://content_staand/shutterstock_105030071.jpg [filemime] => image/jpeg [filesize] => 6251924 [status] => 1 [timestamp] => 1489152377 [rdf_mapping] => Array ( ) [alt] => [title] => [width] => 4928 [height] => 3264 ) ) ) [field_subtitel] => Array ( ) [field_video] => Array ( ) [field_icoon] => Array ( [und] => Array ( [0] => Array ( [fid] => 21 [uid] => 1 [filename] => icon_lifescience.png [uri] => public://industrieen/icon_lifescience.png [filemime] => image/png [filesize] => 313 [status] => 1 [timestamp] => 1376039461 [rdf_mapping] => Array ( ) [alt] => Life Science & Health care [title] => Life Science & Health care [width] => 31 [height] => 31 ) ) ) [field_gerelateerde_producten] => Array ( [und] => Array ( [0] => Array ( [target_id] => 32 ) [1] => Array ( [target_id] => 30 ) [2] => Array ( [target_id] => 28 ) [3] => Array ( [target_id] => 31 ) ) ) [field_gerelateerde_business_vent] => Array ( [und] => Array ( [0] => Array ( [target_id] => 41 ) [1] => Array ( [target_id] => 37 ) [2] => Array ( [target_id] => 52 ) [3] => Array ( [target_id] => 54 ) [4] => Array ( [target_id] => 39 ) [5] => Array ( [target_id] => 36 ) ) ) [field_sortering] => Array ( [und] => Array ( [0] => Array ( [value] => 4 ) ) ) [field_pagina_images] => Array ( ) [rdf_mapping] => Array ( [rdftype] => Array ( [0] => sioc:Item [1] => foaf:Document ) [title] => Array ( [predicates] => Array ( [0] => dc:title ) ) [created] => Array ( [predicates] => Array ( [0] => dc:date [1] => dc:created ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) [changed] => Array ( [predicates] => Array ( [0] => dc:modified ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) [body] => Array ( [predicates] => Array ( [0] => content:encoded ) ) [uid] => Array ( [predicates] => Array ( [0] => sioc:has_creator ) [type] => rel ) [name] => Array ( [predicates] => Array ( [0] => foaf:name ) ) [comment_count] => Array ( [predicates] => Array ( [0] => sioc:num_replies ) [datatype] => xsd:integer ) [last_activity] => Array ( [predicates] => Array ( [0] => sioc:last_activity_date ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) ) [cid] => 0 [last_comment_timestamp] => 1376039461 [last_comment_name] => [last_comment_uid] => 1 [comment_count] => 0 [name] => feyecon-admin [picture] => 0 [data] => a:3:{s:7:"overlay";i:1;s:18:"htmlmail_plaintext";i:0;s:7:"contact";i:0;} ) [access] => 1 ) ) ) [field_pagina_images] => Array ( [und] => Array ( [0] => Array ( [fid] => 261 [uid] => 1 [filename] => Echo.gif [uri] => public://Echo.gif [filemime] => image/gif [filesize] => 84538 [status] => 1 [timestamp] => 1438607170 [rdf_mapping] => Array ( ) [alt] => [title] => [width] => 1077 [height] => 463 ) ) ) [field_attachment] => Array ( ) [rdf_mapping] => Array ( [rdftype] => Array ( [0] => sioc:Item [1] => foaf:Document ) [title] => Array ( [predicates] => Array ( [0] => dc:title ) ) [created] => Array ( [predicates] => Array ( [0] => dc:date [1] => dc:created ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) [changed] => Array ( [predicates] => Array ( [0] => dc:modified ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) [body] => Array ( [predicates] => Array ( [0] => content:encoded ) ) [uid] => Array ( [predicates] => Array ( [0] => sioc:has_creator ) [type] => rel ) [name] => Array ( [predicates] => Array ( [0] => foaf:name ) ) [comment_count] => Array ( [predicates] => Array ( [0] => sioc:num_replies ) [datatype] => xsd:integer ) [last_activity] => Array ( [predicates] => Array ( [0] => sioc:last_activity_date ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) ) [cid] => 0 [last_comment_timestamp] => 1438607126 [last_comment_name] => [last_comment_uid] => 1 [comment_count] => 0 [name] => feyecon-admin [picture] => 0 [data] => a:3:{s:7:"overlay";i:1;s:18:"htmlmail_plaintext";i:0;s:7:"contact";i:0;} [entity_view_prepared] => 1 )